SGMT241220P5000
- 0.50
- 0.000.00%
Sagimet Biosciences Newsroom
Analysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)
Sagimet Started at Outperform by Oppenheimer, MASH Drug Cited
Sagimet Biosciences Price Target Announced at $30.00/Share by Oppenheimer
Oppenheimer Initiates Coverage On Sagimet Biosciences With Outperform Rating, Announces Price Target of $30
JMP Securities Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $31
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sagimet Biosciences Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$141m
Sagimet Biosciences Presents Clinical Denifanstat And Preclinical FASN Inhibitor Data At AASLD The Liver Meeting 2024
Institutional Investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) See US$36m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
Sagimet Biosciences Analyst Ratings
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $32
Sagimet Biosciences Advances MASH Treatment With Denifanstat
Sagimet Biosciences, Inc.: Strategic Advancements and Financial Robustness Drive Buy Rating
Sagimet Biosciences | 8-K: Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Sagimet Biosciences Reports Q3 EPS (45c) Vs (35c) Last Year
Sagimet Biosciences | 10-Q: Q3 2024 Earnings Report
Express News | Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Express News | Sagimet Biosciences Q3 Net Income USD -14.619 Million
Sagimet Biosciences 3Q Loss/Shr 45c >SGMT
Press Release: Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates